<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;VHL&lt;/i&gt;</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>VHL</i></h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>VHL</i></div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Jonasch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donika Saporito, MS, CGC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1844279664"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline testing for the von Hippel-Lindau disease gene, <em>VHL</em>. It does not discuss indications for testing and is not intended to replace clinical judgment in the decision to test or in the clinical care of the individual who was tested. These subjects are discussed separately [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H2187238714"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2644458887"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>There are several important caveats to reviewing a genetic test report; these are summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>). Another table provides a glossary of relevant terminology  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>).</p><p>Testing involves two steps: Analyzing the gene to identify variants and interpreting the pathogenicity of the variant(s) identified.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Analysis</strong> – Identifies variant(s) that differ from a reference sequence. <em>VHL </em>testing includes whole gene sequencing and deletion/duplications analysis. It may evaluate only a subset of possible disease variants in the <em>VHL</em> gene. While variants are expected to be identified if present, current testing technologies may not identify every existing variant. </p><p></p><p class="bulletIndent1">Testing should be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory if the results were obtained by direct-to-consumer testing or a research study in any individual with a personal and/or family history suspicious of VHL. </p><p></p><p class="bulletIndent1">We expect a proportion of positive results from health testing in the general population, especially those obtained from laboratories that are not CLIA-certified and are using microarrays, to be false positives that will not be identified on retesting in a CLIA-certified laboratory using sequencing [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Determines pathogenicity of the variants identified using available data. Variant interpretation may change over time and may require updating as new information becomes available. (See <a class="local">'Classification of variants'</a> below.) </p><p></p><p class="bulletIndent1">For questions regarding the interpretation of a specific variant, the testing laboratory can be contacted for further review. </p><p></p><p class="headingAnchor" id="H114336212"><span class="h2">Classification of variants</span><span class="headingEndMark"> — </span>The pathogenicity of each variant (or lack thereof) is classified by the testing laboratory into one of five categories based on information available to them at the time  (<a class="graphic graphic_table graphicRef122646" href="/z/d/graphic/122646.html" rel="external">table 3</a>) [<a href="#rid3">3</a>]. It is possible for laboratories to have a different classification for the same variant. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive</strong> – Pathogenic or likely pathogenic results indicating von Hippel-Lindau (VHL) disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative</strong> – Benign or likely benign results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncertain</strong> – A variant of uncertain significance (VUS) is a result that needs more information (eg, data from family studies or bench research) before it can be classified as positive or negative. </p><p></p><p>The classification continues to be updated, especially for VUS results, as more information becomes available regarding their associations with disease. Some laboratories routinely provide updates and others require a request for variant reclassification. The uncertainty reflects the available evidence for disease association, not the accuracy of genotyping or the likelihood of disease in a particular individual. Some laboratories may ask for additional clinical information from affected individuals or offer family studies to support or reclassify a variant. Many VUSs are reclassified as benign. Individuals with a VUS in the <em>VHL</em> gene are encouraged to reach out to their ordering clinician or the ordering laboratory every couple of years to determine if a reclassification has been made.</p><p>To learn more about a particular variant, individuals may consult a database such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzGy12ipcVcj41059JRLkL3&amp;TOPIC_ID=126592" target="_blank">ClinVar</a> or a specialist (clinical geneticist, genetic counselor, or specialist in VHL disease). (See <a class="local">'Locating an expert'</a> below.)</p><p>Variants determined to be benign or likely benign are not reported (or are reported as negative). The report may include special interpretations of variants and must be read in its entirety. </p><p class="headingAnchor" id="H3032750909"><span class="h2">Disease associations</span><span class="headingEndMark"> — </span>VHL disease is an autosomal dominant disease caused by a germline pathogenic variant in the <em>VHL</em> gene that predisposes affected individuals to several types of malignant and benign tumors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemangioblastomas (cerebellum, brainstem, spinal cord, retina)</p><p class="bulletIndent2"><span class="glyph">•</span>Middle ear endolymphatic sac tumors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visceral</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal cell carcinomas (clear cell) and renal cysts</p><p class="bulletIndent2"><span class="glyph">•</span>Pheochromocytomas and paragangliomas</p><p class="bulletIndent2"><span class="glyph">•</span>Pancreatic cysts, serous cystadenomas, and neuroendocrine tumors </p><p class="bulletIndent2"><span class="glyph">•</span>Epididymal (males) and broad ligament of the uterus (females) papillary cystadenomas</p><p></p><p>The frequency of tumors and mean age of presentation are summarized in the table  (<a class="graphic graphic_table graphicRef83902" href="/z/d/graphic/83902.html" rel="external">table 4</a>). </p><p><em>VHL</em> is a tumor suppressor gene; development of tumors is thought to occur when a cell (or group of cells) that is heterozygous for a pathogenic variant in<em> VHL</em> loses the normal copy of the gene. There are differences in disease spectrum with different types of pathogenic variants (deletion versus frameshift mutation versus premature stop codon). This creates variable expressivity in disease presentation among individuals and family members with <em>VHL</em>. The mechanisms are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">"Molecular biology and pathogenesis of von Hippel-Lindau disease", section on 'Molecular biology and pathogenesis'</a>.)</p><p class="headingAnchor" id="H265052570"><span class="h1">SURVEILLANCE FOR VHL TUMORS</span><span class="headingEndMark"> — </span>Individuals with a germline pathogenic or likely pathogenic variant in <em>VHL</em> that has been confirmed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (see <a class="local">'How to read the report'</a> above) require active surveillance for associated tumors to allow early intervention when indicated. Surveillance for individuals begins at birth; therefore, confirming a VHL diagnosis in any at-risk family members is important. (See <a class="local">'At-risk relatives'</a> below.)</p><p>VHL disease is rare, and most guidance is based on observational studies and expert opinion. Professional societies may differ slightly in the details of the age at which to start screening, frequency of screening, or screening modality [<a href="#rid4">4-6</a>]. We generally adhere to the recommendations of the VHL Alliance (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.vhl.org%2Fclinicians%2Fsurveillance%2F&amp;token=5CnMhehlb6qiSCK80v48R9lMOqn0Mef4iPG3RFsE%2B4jH5mu6X4JXxOiP1Yy5TPVHHUzub5XCw5Wi1nfdvqAA2Q%3D%3D&amp;TOPIC_ID=126592" target="_blank">VHL.org/clinicians/surveillance/</a>), a patient organization that solicits input from a large group of clinicians with VHL disease expertise [<a href="#rid6">6</a>]. Family history may also be used to tailor screening recommendations. However, VHL can affect individuals differently, even within the same family. </p><p>Caring for individuals with VHL requires a multidisciplinary approach, involving expertise not only in the medical aspects of <em>VHL</em> but also social, genetic, and emotional considerations. History and physical examination is conducted annually from birth (or from the time of diagnosis), including age-appropriate history for visual, vestibuloneural, and catecholamine symptoms and neurologic examination. Recommended surveillance tests are summarized below and in the table  (<a class="graphic graphic_table graphicRef127959" href="/z/d/graphic/127959.html" rel="external">table 5</a>). </p><p>Many of the tumors associated with <em>VHL</em> are benign; however, some have the potential to become malignant.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system tumors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmology (including dilated retinal examination) every 6 to 12 months, starting before age 1 year.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Audiology every 2 years, starting at age 11 years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Magnetic resonance imaging (MRI) with and without contrast of the brain and spine every two years, starting at age 11 years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MRI of the internal auditory canal once at age 15 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visceral tumors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pheochromocytoma and paragangliomas</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Blood pressure and pulse annually, starting at age 2 years.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Metanephrines (plasma free [preferred] or 24-hour urine) annually, starting at age 5 years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal cell cancer, pancreatic tumors, pheochromocytoma, and paragangliomas</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>MRI of the abdomen with and without contrast every two years, beginning at age 15 years.</p><p></p><p>The frequency may be adjusted based on findings (eg, more frequent MRI of the abdomen to monitor tumors &lt;3 cm). MRI contrast is avoided during pregnancy. Surveillance tests can be stopped at age 65 years for individuals who have never had a VHL disease-associated tumor; routine physical examinations and ophthalmology examinations are continued indefinitely. </p><p>VHL confers a significant psychological burden due to uncertainties about when and where a tumor will develop, the need for multiple surgeries over a lifetime, and surgical morbidities. Some individuals may develop postoperative functional impairment or chronic pain. Strategies for stress reduction, counseling, psychosocial support, and/or treatment for depression, anxiety, or opioid use disorder may be indicated. </p><p>For individuals with a family history consistent with VHL disease, negative genetic testing of <em>VHL</em> does not eliminate the need for active surveillance. Alternatively, if a <em>VHL</em> gene mutation is identified in a family and a relative tests negative for the familial mutation with caveats as noted  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>), this is considered to be a true negative result and the individual is not considered to have increased risks associated with VHL disease. </p><p>Referral to a genetic counselor or other individual with expertise in familial cancer syndromes may be especially helpful for advice on additional genetic testing (of <em>VHL </em>or other genes) and/or other clinical surveillance. (See <a class="local">'Locating an expert'</a> below.)</p><p class="headingAnchor" id="H412055877"><span class="h1">MANAGEMENT OF SPECIFIC TUMORS</span><span class="headingEndMark"> — </span>Management of tumors (malignant or benign) in patients with VHL disease is best performed at a VHL clinical care center or a comprehensive cancer center, where optimal approaches can be discussed and implemented. (See  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a>.)</p><p>These experts can take a team decision-making approach that incorporates the individual's complete clinical picture. If in-person care at a VHL center is not possible, consultation with VHL center experts is advised. (See <a class="local">'Locating an expert'</a> below.)</p><p>The following aspects of management may be affected by the presence of a pathogenic or likely pathogenic variant in <em>VHL</em>:</p><p class="bulletIndent1"><span class="glyph">●</span>Possible changes in surgical approach, such as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nephron-sparing surgery for renal cell cancer due to the risk of multifocal, bilateral, and chronologically spaced recurrences or second primary tumors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurosurgical approaches that strike a balance between providing sufficient treatment to prevent or reduce symptoms while also minimizing surgical morbidity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible use of the oral hypoxia-inducible factor (HIF)-2alpha inhibitor <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">belzutifan</a>, which acts downstream of VHL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible investigational therapy or clinical trial targeting VHL-specific mechanism of tumorigenesis or drug sensitivity.</p><p></p><p>Individuals with VHL-related tumors require ongoing surveillance for other tumors (or initiation of surveillance if the VHL diagnosis was previously unknown). (See <a class="local">'Surveillance for VHL tumors'</a> above.)</p><p class="headingAnchor" id="H633990871"><span class="h1">GENETIC TESTING AND COUNSELING</span></p><p>VHL disease is caused by a pathogenic or likely pathogenic variant in the <em>VHL</em> gene. VHL is an autosomal dominant disease and can be inherited by males and females equally. Children of affected individuals have a 50 percent chance of inheriting the causative variant from their parent. </p><p class="headingAnchor" id="H4247117855"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Approximately 80 percent of individuals with VHL disease have an affected parent; the remaining 20 percent have a de novo mutation (new in an individual for the first time) [<a href="#rid7">7</a>]. Thus, it is reasonable when a new diagnosis is made in a family to test the parents for the variant first  (<a class="graphic graphic_algorithm graphicRef128058" href="/z/d/graphic/128058.html" rel="external">algorithm 1</a>), with subsequent testing of other first-degree relatives and cascade testing of their first-degree relatives based on the results. </p><p>Genetic counseling and genetic testing for first-degree relatives are important as they help to identify which individuals have increased risks necessitating additional surveillance and which do not. </p><p>Individuals with a pathogenic or likely pathogenic variant in <em>VHL</em> should inform their first-degree relatives about the importance of genetic counseling and testing. Results should be shared within a family to ensure accurate single-site genetic testing for at-risk relatives. </p><p>Testing should be performed as soon as possible for family members who are at risk for carrying a germline pathogenic or likely pathogenic variant in <em>VHL</em>. Testing can occur soon after birth for newborn children of affected individuals based on the early onset of disease manifestations. </p><p class="headingAnchor" id="H2440551444"><span class="h2">Preconception counseling</span><span class="headingEndMark"> — </span>Some individuals may choose to pursue reproductive options such as donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.) </p><p class="headingAnchor" id="H3694321033"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H560221511"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pathogenesis – (See  <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">"Molecular biology and pathogenesis of von Hippel-Lindau disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis and management – (See  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a>.)</p><p></p><p class="headingAnchor" id="H971172137"><span class="h2">Locating an expert</span><span class="headingEndMark"> — </span>Listings are available from the following organizations:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=126592" target="_blank">ACMG</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=126592" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>National Institutes of Health (NIH) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=126592" target="_blank">Cancer Genetics Services Directory</a></p><p class="bulletIndent1"><span class="glyph">●</span>VHL Clinical Care Centers – The VHL Alliance has lists for the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.vhl.org%2Fabout%2Fresources%2Fclinical-care-centers-directory%2Fus-clinical-care-centers%2F&amp;token=WrITxb6q9WaQ5%2B20reA37gs7IHDhVI9jJDj1xllPECcUmCZgEWimK%2BD5x5rmPPjHcYIy6vt7kN93Neqic3yIWAwTzicIxYbX%2BFeByWhpUBE%3D&amp;TOPIC_ID=126592" target="_blank">United States</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.vhl.org%2Fabout%2Fresources%2Fclinical-care-centers-directory%2Finternational-clinical-care-centers%2F&amp;token=63SCLRf2SU9FDKTMGjlvwi2eSqISmDiHvVEgoAqnJ1wvULajvF0HCiA5fQbEbeR3vPJvcYE%2B%2FAd1OHFcRlFX8vSlfRBmTsjcjpBLfpZo90w%3D&amp;TOPIC_ID=126592" target="_blank">International</a> </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med 2018; 20:1515.</a></li><li><a class="nounderline abstract_t">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.</a></li><li><a class="nounderline abstract_t">Binderup ML, Bisgaard ML, Harbud V, et al. Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J 2013; 60:B4763.</a></li><li><a class="nounderline abstract_t">Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res 2017; 23:e68.</a></li><li class="breakAll">https://www.vhl.org/clinicians/surveillance/ (Accessed on July 24, 2020).</li><li><a class="nounderline abstract_t">Varshney N, Kebede AA, Owusu-Dapaah H, et al. A Review of Von Hippel-Lindau Syndrome. J Kidney Cancer VHL 2017; 4:20.</a></li></ol></div><div id="topicVersionRevision">Topic 126592 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565420" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355456" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620007" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620007" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28785532" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A Review of Von Hippel-Lindau Syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
